<DOC>
	<DOC>NCT02652624</DOC>
	<brief_summary>This study will evaluate the efficacy of switching to a fixed-dose combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus continuing on a regimen consisting of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF), elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF), or atazanavir (ATV) + ritonavir (RTV) + emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) in virologically suppressed HIV-1 infected women.</brief_summary>
	<brief_title>Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<criteria>Key Inclusion Criteria Medically stable HIV1 infected women who meet the following criteria: Completion of the Week 48 openlabel extension (OLE) visit or any post Week 48 OLE visits in Gileadsponsored study GS US 236 0128, or Completion of the Week 96 visit or any post Week 96 visits in Gileadsponsored study GS US2920109 or completion of the Week 144 visit or any post Week 144 visits in Gilead sponsored studies GSUS2920104 or GSUS2920111. Currently on a stable antiretroviral regimen consisting of E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF continuously for ≥ 12 consecutive weeks preceding the screening visit Documented plasma HIV1 RNA levels &lt; 50 copies/mL for ≥ 12 weeks preceding the Screening visit. After reaching HIV1 RNA &lt; 50 copies/mL, single values of HIV1 RNA ≥ 50 copies/mL followed by resuppression to &lt; 50 copies/mL is allowed HIV1 RNA &lt;50 copies/mL at screening Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min (≥ 0.83 mL/sec) according to the CockcroftGault formula at the screening visit Note: Other Protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>